imatinib mesylate has been researched along with Hypertension, Portal in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Das, A; Kang, N; Langer, D; Leof, E; Semela, D; Shah, V | 1 |
| Csete, M; Heffron, T; Knowles, D; Lawrence, EC; Tapper, EB | 1 |
| Bosch, J; Fernandez, M; Garcia-Pagan, JC; Garcia-Pras, E; Mejias, M; Mendez, R | 1 |
3 other study(ies) available for imatinib mesylate and Hypertension, Portal
| Article | Year |
|---|---|
Platelet-derived growth factor signaling through ephrin-b2 regulates hepatic vascular structure and function.
Topics: Animals; Becaplermin; Benzamides; Capillary Permeability; Cells, Cultured; Coculture Techniques; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Ephrin-B2; Humans; Hypertension, Portal; Image Processing, Computer-Assisted; Imatinib Mesylate; Liver; Mice; Microscopy, Confocal; Microscopy, Video; Neovascularization, Physiologic; NIH 3T3 Cells; Pericytes; Phenotype; Piperazines; Platelet-Derived Growth Factor; Portal Pressure; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrimidines; Rats; Receptors, Platelet-Derived Growth Factor; RNA Interference; Signal Transduction; Time Factors; Transfection | 2008 |
Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition.
Topics: Antihypertensive Agents; Benzamides; Bosentan; Epoprostenol; Female; Humans; Hypertension, Portal; Hypertension, Pulmonary; Imatinib Mesylate; Liver Failure; Liver Transplantation; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Treatment Outcome | 2009 |
Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
Topics: Animals; Benzamides; Disease Models, Animal; Drug Therapy, Combination; Hypertension, Portal; Imatinib Mesylate; Immunosuppressive Agents; Ligation; Male; Mesenteric Artery, Superior; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Portal Vein; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Signal Transduction; Sirolimus; Splanchnic Circulation; Vascular Endothelial Growth Factor A | 2007 |